Marvel Biosciences to Run MB-204 Phase 1 Trial in Australia

Marvel Biosciences has signed a letter of intent with Novatech to manage Phase 1 trials of its drug candidate MB-204 in Australia. This agreement covers both single ascending dose (SAD) and multiple ascending dose (MAD) studies, marking a progression from preclinical development toward first-in-human testing.